Response to "Ipilimumab (Yervoy) and the TGN1412 catastrophe" Journal Article

  

Authors:	Curran, M. A.; Callahan, M. K.; Subudhi, S. K.; Allison, J. P.
Article Title:	Response to "Ipilimumab (Yervoy) and the TGN1412 catastrophe"
Keywords:	treatment outcome; diarrhea; drug efficacy; drug safety; nonhuman; risk benefit analysis; temozolomide; letter; dacarbazine; ipilimumab; melanoma; skin neoplasms; drug fatality; t lymphocyte receptor; regulatory t lymphocyte; antibodies, monoclonal; molecular recognition; drug response; colitis; ctla-4; cytotoxic t lymphocyte antigen 4; drug binding; t lymphocyte activation; cd28 antigen; b7 antigen; tgn 1412; cd28; immunization, passive; cardiogenic shock; cytokine storm; ctla-4 antigen
Journal Title:	Immunobiology
Volume:	217
Issue:	6
ISSN:	0171-2985
Publisher:	Elsevier Inc.
Date Published:	2012-06-01
Start Page:	590
End Page:	592
Language:	English
DOI:	10.1016/j.imbio.2011.11.001
PROVIDER:	scopus
PUBMED:	22459268
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-84860234605&partnerID=40&md5=a6215c23b3dcc207b2310a4258c20534
Notes:	--- - "Export Date: 4 June 2012" - "CODEN: ZIMMD" - "Source: Scopus"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/28436